+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Trigeminal Neuralgia - Pipeline Insight, 2021

  • ID: 5237652
  • Drug Pipelines
  • January 2021
  • Region: Global
  • 60 pages
  • DelveInsight

FEATURED COMPANIES

  • Amgen
  • Biogen
  • Biohaven Pharmaceuticals
  • Grace Therapeutics
  • Tonix Pharmaceuticals
This “Trigeminal Neuralgia - Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Trigeminal Neuralgia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
  • Global coverage
Trigeminal Neuralgia Understanding

Trigeminal Neuralgia: Overview

Trigeminal Neuralgia is a chronic neuropathic pain disorder characterized by spontaneous and elicited paroxysms of electric shock-like or stabbing pain in a region of the face. The pain of trigeminal neuralgia most frequently affects the distribution of the second (maxillary) or third (mandibular) division of the trigeminal nerve, with the right side of the face affected more often than the left side. Three types of trigeminal neuralgia have been delineated: classical, secondary, and idiopathic. Bilateral trigeminal neuralgia is rare and should raise concern about facial neuralgia due to an underlying neurologic disease or a non-neurologic disorder affecting the cranium. The incidence of trigeminal neuralgia is higher among women than among men and increases with age.

Symptoms

The pain of Trigeminal Neuralgia can come in sharp spasms that feel like electric shocks. Pain generally occurs on one side of the face and may be brought on by sound or touch. Pain can be triggered by routine acts, including: brushing teeth, shaving, touching face, eating or drinking, speaking, a breeze on face etc.

Diagnosis

The diagnosis of trigeminal neuralgia is clinical and is based on three main criteria: pain restricted to the territory of one or more divisions of the trigeminal nerve; paroxysms of pain that are sudden, intense, and very short. Diagnosis will depend on the type and location of the pain and factors that trigger the pain.

Treatment

The anticonvulsant agents carbamazepine, in doses of approximately 200 to 1200 mg per day, and oxcarbazepine (300 to 1800 mg per day) have been considered the first-choice treatments for control of paroxysmal pain in patients with trigeminal neuralgia, regardless of the cause. Gabapentin, pregabalin, and antidepressant agents, which have been shown to be effective in the treatment of other neuropathic conditions characterized by continuous pain, may be tried as additional agents along with oxcarbazepine or carbamazepine. Microvascular decompression has become the surgical procedure that is now favored for most cases of trigeminal neuralgia that do not respond to medication.

Trigeminal Neuralgia Emerging Drugs Chapters

This segment of the Trigeminal Neuralgia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Trigeminal Neuralgia Emerging Drugs

Vixotrigine: Biogen

Vixotrigine (BIIB074) is a voltage and use-dependent sodium channel blocker. It is a centrally and peripherally acting small molecule. It is being developed by Biogen for the treatment of Trigeminal Neuralgia.

Rimegepant: Biohaven Pharmaceuticals

Rimegepant is a Phase 2 calcitonin gene-related peptide receptor antagonists. It is being developed by Biohaven pharmaceuticals. The trail got initiated in June 2019 and is expected to get completed by October 2021 with expected 30 enrolled participants. (NCT03941834)

Trigeminal Neuralgia: Therapeutic Assessment

This segment of the report provides insights about the different Trigeminal Neuralgia drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Trigeminal Neuralgia

There are approx. 10+ key companies which are developing the therapies for Trigeminal Neuralgia. The companies which have their Trigeminal Neuralgia drug candidates in the most advanced stage, i. e. phase III include, Biogen.

Phases

This report covers around 10+ products under different phases of clinical development like
  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration
Trigeminal Neuralgia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Oral
  • Parenteral
  • intravitreal
  • Subretinal
  • Topical.
  • Molecule Type
Products have been categorized under various Molecule types such as
  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Trigeminal Neuralgia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Trigeminal Neuralgia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Trigeminal Neuralgia drugs.

Report Highlights
  • The companies and academics are working to assess challenges and seek opportunities that could influence Trigeminal Neuralgia R&D. The therapies under development are focused on novel approaches to treat/improve Trigeminal Neuralgia.
Trigeminal Neuralgia Report Insights
  • Trigeminal Neuralgia Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs
Trigeminal Neuralgia Report Assessment
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs
Key Questions Answered

Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing Trigeminal Neuralgia drugs?
  • How many Trigeminal Neuralgia drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Trigeminal Neuralgia?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Trigeminal Neuralgia therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Trigeminal Neuralgia and their status?
  • What are the key designations that have been granted to the emerging drugs?
Key Players
  • Biogen
  • Biohaven Pharmaceuticals
  • Amgen
  • Grace Therapeutics
  • Tonix Pharmaceuticals
Key Products
  • Vixotrigine
  • Rimegepant
  • Erenumab
  • GTX201
  • TNX-1900

This report will be delivered within 1-3 business days
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Amgen
  • Biogen
  • Biohaven Pharmaceuticals
  • Grace Therapeutics
  • Tonix Pharmaceuticals
Introduction

Executive Summary

Trigeminal Neuralgia: Overview
  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management
Pipeline Therapeutics
  • Comparative Analysis
Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type
Trigeminal Neuralgia - Analytical Perspective

In-depth Commercial Assessment
  • Trigeminal Neuralgia companies’ collaborations, Licensing, Acquisition - Deal Value Trends
Trigeminal Neuralgia Collaboration Deals
  • Company-Company Collaborations (Licensing / Partnering) Analysis
  • Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
  • Comparative Analysis
Vixotrigine: Biogen
  • Product Description
  • Research and Development
  • Product Development Activities
Mid Stage Products (Phase II)
  • Comparative Analysis
Rimegepant: Biohaven Pharmaceuticals
  • Product Description
  • Research and Development
  • Product Development Activities
Early Stage Products (Phase I)
  • Comparative Analysis
GTX201: Grace Therapeutics
  • Product Description
  • Research and Development
  • Product Development Activities
Pre-clinical and Discovery Stage Products
  • Comparative Analysis
TNX-1900: Tonix Pharmaceuticals
  • Product Description
  • Research and Development
  • Product Development Activities
Inactive Products
  • Comparative Analysis
Trigeminal Neuralgia Key Companies

Trigeminal Neuralgia Key Products

Trigeminal Neuralgia- Unmet Needs

Trigeminal Neuralgia- Market Drivers and Barriers

Trigeminal Neuralgia- Future Perspectives and Conclusion

Trigeminal Neuralgia Analyst Views

Trigeminal Neuralgia Key Companies

Appendix

List of Tables
Table 1 Total Products for Trigeminal Neuralgia
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List of Figures
Figure 1 Total Products for Trigeminal Neuralgia
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Note: Product cover images may vary from those shown
  • Biogen
  • Biohaven Pharmaceuticals
  • Amgen
  • Grace Therapeutics
  • Tonix Pharmaceuticals
Note: Product cover images may vary from those shown
Adroll
adroll